Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
about
Antidepressants for depression during pregnancyA meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weightPharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approachAntidepressant use in pregnancy: a critical review focused on risks and controversiesSelective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.Prenatal antidepressant exposure: clinical and preclinical findings.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade.Continuing medical education: SSRIs and pregnancy.Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapyIn utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder.Pregnant women with posttraumatic stress disorder and risk of preterm birthAntidepressant use in pregnant and postpartum womenLength of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Developmental exposure to fluoxetine modulates the serotonin system in hypothalamus.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm birth.Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Acculturation, depressive symptoms, estriol, progesterone, and preterm birth in Hispanic women.Maternal Use of Selective Serotonin Reuptake Inhibitors and Lengthening of the Umbilical Cord: Indirect Evidence of Increased Foetal Activity-A Retrospective Cohort Study.Mediators of adverse birth outcomes among socially disadvantaged women.Depression in pregnancy, infant birth weight and DNA methylation of imprint regulatory elementsDepression and serotonin reuptake inhibitor treatment as risk factors for preterm birth.Is the Risk of Preterm Birth and Low Birth Weight Affected by the Use of Antidepressant Agents during Pregnancy? A Population-Based InvestigationMaternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies.Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study.Placental serotonin: implications for the developmental effects of SSRIs and maternal depressionThe effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspringOf rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research.Use of selective serotonin reuptake inhibitors and lifestyle among women of childbearing age: a Danish cross-sectional survey.Effects of maternal psychotropic drug dosage on birth outcomes.Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.A pharmacological approach to panic disorder during pregnancy.Use of psychotropic drugs during pregnancy and breast-feeding.Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring.Prenatal exposure to antidepressants and risk of epilepsy in childhood.
P2860
Q24200798-19161A67-0287-4916-BE7B-647AC57E0FADQ24623163-3A578964-6D44-4084-99BF-2C97317F0455Q26774013-5BB640D4-F5C6-43C7-BB10-3FDA12711FE6Q28281407-39317199-0A2C-445C-9F98-2141CC3D7E9AQ30244451-97798B29-A16F-467F-A9B7-20C38800F4EEQ30415540-25D7B08E-9954-4859-80CF-1D4FDAB72875Q33521786-6AB615F2-06E2-45F3-AC33-E3BA8D6AE02FQ33614127-36487DA0-3D57-4B63-9C7A-1C38D8EA309DQ33671166-13B5AAD0-A34E-47C2-A6FF-6DAD99CB295FQ33745085-6EE083A2-D6C3-41AE-859F-9CD33EB29E4DQ34040844-4BFD5140-BD96-461A-A240-F412462E491DQ34053512-D96C47F4-E562-4964-B5E4-1800CFDD2FADQ34068023-4CE5CAC9-DA95-4B8E-89AA-A102E4CA5377Q34178991-245F765B-C38A-49B1-A060-1EC8B3A47C7CQ34576006-09DEE440-CD2C-436E-8AB3-A8A257CF681AQ34623350-542F6955-4FA7-4F31-BC2B-69346EA09735Q34796345-B70C1697-CD58-4EE7-97B5-425BADF9AB2DQ35132422-8AA3A209-13BD-44B7-8DC3-102A18B35436Q35608913-9A0DBAD8-FEF4-4F7E-AFA3-87A04A18B95BQ35928380-82269B6B-406D-4721-9EBA-4829718E0076Q36002891-2A4FCC7A-D8D8-4600-9747-74F9B9A12AAFQ36004276-E14A90F4-9DFB-40B8-AFE6-4FBB26DAE745Q36149236-8E9B4F12-D129-43B1-901C-AC3786E29685Q36152982-96911D6F-2F24-470C-9E1D-930492755F9BQ36225011-A4A67B8F-E7A5-4E59-9EA2-CB463A35DBFBQ36596080-8096DCFB-23BD-4227-B94B-2AEDF22680BBQ36779955-5A373842-DF03-4362-8306-07E52A132262Q36785491-3E1DEEF3-9CBA-4268-BFE3-D44C91CC0713Q36860205-19E9ED15-E3E0-44CF-980B-ED521E804EDAQ37058701-39D1B6DC-8966-4504-98AF-B580793C681CQ37065238-3E58E25E-4A78-460B-BDDE-AF6858FD3496Q37397151-B49A87B5-4E0E-4D90-9E26-AB4DCF8365A2Q37943435-0E724EB3-CA1D-4C2A-B197-43E0305F18ADQ38040821-B54ACBD1-38A6-4A95-913B-2ED509E0C1F2Q38215072-49CA0CB0-BDBD-49D4-B9EE-BBE70A78EF16Q38305749-66747C25-0E39-4619-BA88-8620073C9D41Q38516009-891699A2-C033-40BB-9517-7255DEC910A7Q38582061-39E7C388-3152-417E-B3DA-D27F14E527AAQ40125660-00049FD8-8F09-46F3-91BD-DF38B82380DDQ40498883-8B97D8AD-4023-4C13-8182-D99DBABA0F9B
P2860
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@en
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@nl
type
label
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@en
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@nl
prefLabel
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@en
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@nl
P1433
P1476
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
@en
P2093
Najaaraq Lund
Tine Brink Henriksen
P304
P356
10.1001/ARCHPEDIATRICS.2009.164
P407
P577
2009-10-01T00:00:00Z